Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Yuffa Ilya

LILLY ENDOWMENT INC

While Eli Lilly's GLP-1 weight-loss drugs (Mounjaro and Zepbound) account for nearly two-thirds of revenues with strong growth, the company is strategically using profits from these drugs to build a diversified pipeline in immunology, oncology, and neuroscience through acquisitions like AtaiBeckley and Ventyx Biosciences. Non-weight-loss drugs are already showing 160% revenue growth, positioning Eli Lilly for long-term success beyond the limited patent life of GLP-1 drugs.

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss

Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positioned in the fast-growing anti-obesity market with strong pipelines.

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in January 2020, averaging over 57% annually, by identifying clinically differentiated technologies before mainstream market recognition.

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

AtaiBeckley shares surged 33.40% after pharmaceutical giant Eli Lilly agreed to acquire the mental health-focused biotechnology company for $6.75 per share in cash, plus up to $2.50 per share in milestone payments. The total deal valuation could reach approximately $3.8 billion if all conditions are met. The acquisition is expected to close in Q3, subject to shareholder and regulatory approval.

Why AtaiBeckley Stock Soared Today

The iShares Global Healthcare ETF (IXJ) outperformed the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) over the past five years, delivering stronger total returns (1.50% dividend yield vs. 0.70%), lower volatility (beta of 0.56 vs. 0.78), and a shallower maximum drawdown. While both funds charge identical 0.40% expense ratios, IXJ's market-cap weighting and international exposure of 110 global healthcare stocks provide broader diversification compared to RSPH's 60 U.S. large-cap equal-weighted holdings.

Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

Professional Trader, 10+ years experience - Founder at https://t.co/oHBJyNQTZd and https://t.co/GEJpgVvdaY.

Alex Desjardins

J.C. Parets

He who hath ears to hear, let him hear ▪️sweeper fetish ▪️ equity market handicapper & speculator since '97 ▪️l7-day trial ?? https://t.co/YSzVEQH8EA

WALL ST JESUS

Trading & Investing Education 
Inventor : Ripster Cloud System  
Founder: Tenet Trade Group
https://t.co/0qpaN2fM0W
 https://t.co/GP2vE0fon3

Eli Lilly and Company (LLY) Stock Price, Analysis & Trade Signals